The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global binder excipients market was valued at US$ 1.4 Billion in 2022.
We expect the global binder excipients market to exhibit a CAGR of 4.5% during 2023-2028.
The rising prevalence of several chronic and seasonal diseases, along with the increasing demand for binder excipients to improve disintegration, bulkiness, bioavailability, and dissolution rate of the drug, is primarily driving the global binder excipients market.
The sudden outbreak of the COVID-19 pandemic has led to the escalating adoption of binder excipients in generic drug manufacturing for treating the coronavirus-infected patients.
Based on the product type, the global binder excipients market has been segregated into cellulosics, lactose, polyols, povidones, starch and polysaccharides, co-processed compressible excipients, and others. Among these, cellulosic excipients hold the largest market share.
Based on the application, the global binder excipients market can be bifurcated into tablets and capsules and solution based. Currently, tablets and capsules exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global binder excipients market include Colorcon, Croda International, EMD Millipore, Dow Chemical, FMC BioPolymer, Fuji Chemical Industry, and Ingredion.
Gastric Cancer Drugs Market by Type (Doxorubicin hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at